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A Small Molecule That Increases Apolipoprotein A-I
and High-Density Lipoprotein Cholesterol In Vitro and In Vivo
Dana Bailey, MSC,* Ravi Jahagirdar, DVM, MS,† Allan Gordon, MD, PHD,† Anouar Hafiane, MSC,*
Steven Campbell, BSC,* Safia Chatur, BSC,* Gregory S. Wagner, PHD,† Henrik C. Hansen, PHD,†
Fabrizio S. Chiacchia, MBT,† Jan Johansson, MD, PHD,† Larbi Krimbou, DES,*
Norman C. W. Wong, MD,† Jacques Genest, MD*
Montréal, Québec, and Calgary, Alberta, Canada
Objectives The aim of this study was to determine whether a novel small molecule RVX-208 affects apolipoprotein (apo)A-I
and high-density lipoprotein cholesterol (HDL-C) levels in vitro and in vivo.
Background Increased apoA-I and HDL-C levels are potential therapeutic targets for reducing atherosclerotic disease.
Methods HepG2 cells were treated with 0 to 60 mol/l RVX-208 followed by assays for apoA-I and HDL-C production. For
in vivo studies, African green monkeys (AGMs) received 15 to 60 mg/kg/day RVX-208, and the serum was ana-
lyzed for lipoprotein levels, HDL-subparticle distribution, cholesterol efflux, and activity of lipid-modifying en-
zymes. A phase I clinical trial was conducted in healthy volunteers (given 1 to 20 mg/kg/day of RVX-208) to as-
sess safety, tolerability, and pharmacokinetics.
Results The RVX-208 induced apoA-I messenger ribonucleic acid and protein synthesis in HepG2 cells, leading to in-
creased levels of pre--migrating and -lipoprotein particles containing apoA-I (LpA-I) in spent media. Similarly,
in AGMs, RVX-208 treatment for 63 days increased serum apoA-I and HDL-C levels (60% and 97%, respectively).
In addition, the levels of pre-1-LpA-I and 1-LpA-I HDL-subparticles were increased as well as adenosine triphos-
phate binding cassette AI, adenosine triphosphate binding cassette G1, and scavenger receptor class B type
I-dependent cholesterol efflux. These changes were not mediated by cholesteryl-ester-transfer protein. Treatment
of humans for 1 week with oral RVX-208 increased apoA-I, pre--HDL, and HDL functionality.
Conclusions RVX-208 increases apoA-I and HDL-C in vitro and in vivo. In AGMs, RVX-208 raises serum pre-1-LpA-I and
-LpA-I levels and enhances cholesterol efflux. Data in humans point to beneficial features of RVX-208 that
might be useful for treating atherosclerosis. (J Am Coll Cardiol 2010;55:2580–9) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.035r
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raising plasma levels of high-density lipoprotein cholesterol
HDL-C) with small molecules that up-regulate apoli-
oprotein A-I (apoA-I) expression has been a therapeutic
oal in cardiovascular medicine for more than 2 decades.
lthough current treatments for atherosclerotic cardiovas-
ular disease (ACVD) are dominated by lowering low-
ensity lipoprotein cholesterol (LDL-C), intervention trials
ighlight the benefits of raising HDL-C (1,2). The idea to
rom the *Division of Cardiology, McGill University Health Center/Royal Victoria
ospital, Montréal, Québec, Canada; and the †Resverlogix Corporation, Calgary,
lberta, Canada. This research was supported by Resverlogix Corp., CIHR Grants
OP-15042 (to Drs. Krimbou and Genest), and HSF of Québec. Ms. Bailey, Dr.
agner, Dr. Johansson, and Dr. Wong are employees of and have stock options with
esverlogix. Dr. Gordon is an employee of and gets a salary from Resverlogix. Dr.
ansen and Mr. Chiacchia are employees of Resverlogix. Ms. Bailey, Dr. Jahagirdar,
nd Dr. Gordon contributed equally to this work.i
Manuscript received August 19, 2009; revised manuscript received January 8, 2010,
ccepted February 1, 2010.aise HDL stems from the consistent inverse correlation of
CVD with plasma HDL-C (3). Indeed, animal studies
ave shown that infusion of HDL or apoA-I or genetic
verexpression of apoA-I limits progression and reduces
re-existing atherosclerosis (2). Additionally, a recent hu-
an trial demonstrated reduction of atheroma volume by
irect infusion of pre- HDL-like particles comprising
poA-I Milano and phospholipids (4). These outcomes
upport interest in apoA-I and HDL-C as major therapeu-
ic targets to potentially reduce ACVD.
Additionally, evidence suggests that HDL and apoA-I
ossess pleiotropic properties that might contribute to their
nti-atherogenic effects (5), such as anti-inflammatory (6),
nti-oxidative (7), and antithrombotic activities (8). How-
ver, the best-recognized property of HDL is its proposed
ole in retrieving excess cholesterol from peripheral cells,
ncluding vessel wall macrophages, via specific transporters
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June 8, 2010:2580–9 Effect of RVX-208 Compound on HDL Metabolisme.g., the adenosine triphosphate-binding cassette proteins
BCA1 and ABCG1 and scavenger receptor BI [SR-B1])
n route to the liver for excretion into the bile. It is widely
ccepted that apoA-I is a critical mediator of this reverse
holesterol transport (RCT) process (1,2).
Although a variety of HDL/apoA-I–based therapies are
nder investigation, raising endogenous apoA-I expression is
enerally considered the most enviable approach to target
DL. The goal to raise HDL-C particles is tempered by the
act that increased levels do not necessarily equal better out-
ome. For example, the cholesteryl-ester-transfer protein
CETP) inhibitor torcetrapib raised levels of HDL particles
ut failed to reduce atherosclerotic burden (9). Similarly,
nalysis of the IDEAL (Incremental Decrease in Endpoints
hrough Aggressive Lipid lowering) and EPIC-Norfolk (Eu-
opean Prospective Investigation Into Cancer in Norfolk) data
howed that very high HDL-C mass and size correlated with
CVD. These findings point to the complexity of HDL
iology and suggest that not only HDL-C levels but also size,
omposition, and functionality are important. The current
tudy examined the potential of a novel small molecule,
VX-208, to increase apoA-I, HDL levels, and HDL func-
ion in liver cells, African Green monkeys (AGMs) and
umans.
ethods
epG2 cell and metabolic pulse-chase studies. HepG2
ells were treated with RVX-208 (0 to 60 mol/l) for 48 h
n minimum essential medium 0.5% fetal bovine serum.
otal ribonucleic acid was isolated (Isogen reagent), and
elative APOA1 messenger ribonucleic acid (mRNA) ex-
ression was determined against endogenous cyclophillin
7500 RT-PCR System, Applied Biosystems, Foster City,
alifornia). To determine the effect of RVX-208 on the
roduction of apoA-I, HepG2 were treated with or without
VX-208 (60 mol/l) for different time periods, and the
poA-I content of the media as well as the cell lysates was
nalyzed by sodium dodecyl sulfate polyacrylamide gel
lectrophoresis and 2-dimensional polyacrylamide nonde-
aturing gradient gel electrophoresis (2D-PAGGE). For
ulse-chase studies, HepG2 cells treated with or without
VX-208 (60 mol/l) were pulsed with 150 Ci/ml [35S]
ethionine/cysteine in serum free-RPMI for 10 min and
hen chased with 5 mmol/l methionine/cysteine. Immuno-
recipitation, sodium dodecyl sulfate polyacrylamide gel
lectrophoresis, and fluorography were performed on cell
ysates and spent media in duplicate.
GM study. Naïve adult male AGMs (Chlorocebus aethiops
abaeus, 4.0 to 5.7 kg, housed at Barbados Primate Research
enter) were fed ad libitum (Teklad global 2050 diet,
eklad, Madison, Michigan). All animals were fasted for
2 h before sample collection. All studies adhered to the
are and Use of Laboratory Animals (as per National
nstitutes of Health Publication No. 86-23, revised 1996)
nd were approved by the Institutional Animal Care and 2se Committee in accordance
ith National Institutes of Health
Office for Protection from Re-
earch Risks) and U.S. Depart-
ent of Agriculture Animal and
lant Health Inspection Service.
n single-dose studies, 6 AGMs
ere given 60 mg/kg RVX-208
nce daily dissolved in 1N hydro-
hloride and carboxymethyl cellu-
ose (pH  2.5 to 3.0) or vehicle
or 63 days followed by a 2-week
ashout. Serum samples were
aken on days 21, 28, 42, and
3 and at 1 and 14 days after
nal dosing. For the dose re-
ponse study, AGMs (6/group)
ere given vehicle or 7.5, 15, or
0 mg/kg of RVX-208 twice a
ay for 73 days before 11 days of
ashout. Samples were taken on
ays 14, 28, 42, 56, 70, and 73 and
t 4 and 11 days after final dosing.
ynomolgus monkey study.
ale young adult cynomolgus
onkeys (n 3) were fasted over-
ight before the administration of
arying doses of RVX-208 via oral
avage or intravenously for phar-
acokinetic studies. Food was
ithheld during the first 4 h after
osing but not for subsequent
lood sampling (femoral or jugular
enipuncture) up to 48 h. All stud-
es were conducted in accordance
ith MPI Research (Mattawan,
ichigan) standard operating pro-
edures, and to ensure compliance
he protocol was reviewed and ap-
roved by the Institutional Animal
are and Use Committee.
VX-208 administration in
umans. To study the effects
f RVX-208, healthy volunteers
ere confined to a study center (PPD, Austin, Texas) 1 day
efore and released shortly after treatment. All subjects
onsented to the study as approved by the IntegReview
thical Review Board (Austin, Texas), which complied
ith the Declaration of Helsinki 2000. The RVX-208 was
uspended in Ora-Blend SF (Paddock Laboratories, Min-
eapolis, Minnesota); Ora-Blend SF served as placebo. Six
ubjects received 1 mg/kg, and an equal number were given
mg/kg RVX-208 twice a day for 6 days, followed by a
ingle dose on day 7. Six other subjects were given 3 mg/kg
VX-208 once daily for 7 days. In total the subjects received
Abbreviations
and Acronyms
2D-PAGGE  2-dimensional
polyacrylamide non-
denaturing gradient gel
electrophoresis
ABCA1  adenosine
triphosphate binding
cassette AI
ABCG1  adenosine
triphosphate binding
cassette GI
ACVD  atherosclerotic
cardiovascular disease
AGM  African green
monkey
apo  apolipoprotein
BHK  baby hamster
kidney
CETP  cholesteryl-ester-
transfer protein
FER  fractional
cholesterol esterification
rate
HDL  high-density
lipoprotein
HDL-C  high-density
lipoprotein cholesterol
LCAT  lecithin:cholesterol
acyl transferase
LDL-C  low-density
lipoprotein cholesterol
LpA-I  lipoprotein
particles containing apoA-I
mRNA  messenger
ribonucleic acid
ND-PAGGE  non-
denaturing gradient gel
electrophoresis
PLTP  phospholipid
transfer protein
RCT  reverse cholesterol
transport
SR-BI  scavenger
receptor class B type Ito 8 mg/kg/day of RVX-208. There were 2 control
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Effect of RVX-208 Compound on HDL Metabolism June 8, 2010:2580–9ubjects in each of the 3 groups who received placebo.
ampling of clinical parameters was collected before dosing
n day 1 and after dose administration on days 1, 2, 4, 7,
nd 10. Pharmacodynamic data were expressed with the
ollowing formula:
[Day7RVX-208  Day1,pre-treatmentRVX-208]/
Day1,pre-treatmentRVX-208)  ([Day7Placebo – Day1,
pre-treatmentPlacebo]/Day1,pre-treatmentPlacebo)  100
nalysis of HDL species. Nondenaturing gradient gel elec-
rophoresis (ND-PAGGE) 5% to 35% was performed as
reviously described (9) on serum (25 l) along with radiola-
eled molecular weight standards. apoA-I–containing particles
ere detected with an anti-human-apoA-I antibody (Biode-
ign, Bar Harbor, Maine) or an anti-monkey–apoA-I antibody
rom Dr. J. Parks (Wake Forest University, Winston-Salem,
orth Carolina) and quantitated with densitometry. Abun-
ance of apoA-I in each HDL subfraction was expressed as a
ercentage of the total. Differences in HDL subclass distribu-
ion between vehicle and RVX-208–treated monkeys were
etermined by 2-tailed t test.
BCA1, ABCG1, and SR-BI-cholesterol efflux. Cells
J774, Fu5AH, or baby hamster kidney [BHK] overexpress-
ng ABCG1 under mifepristone-induction) were labeled
ith 3 Ci/ml 3H-free cholesterol (Perkin Elmer, Norwalk,
onnecticut) for 24 h. Simultaneously, J774 cells were incu-
ated with 2 g/ml ACAT inhibitor (Pfizer, New York, New
ork). Afterward, J774 and BHK-ABCG1 were stimulated
ith 0.5 mmol/l 8-Br-cyclic adenosine monophosphate or 10
mol/l mifepristone for 18 h, respectively (10). Cells were
ncubated with 2% serum for 4 h at 37°C. The %cholesterol
fflux  3H-cpmmedium/(
3H-cpmmedium
3H-cpmcells) 
00%. Human apoA-I and standard human serum were
nalyzed in parallel with test samples. The J774-efflux was
ormalized by the lipid-free apoA-I-efflux, whereas Fu5AH-
nd BHK-ABCG1-efflux was normalized by the serum
tandard-efflux. Cholesterol efflux from nonstimulated cells
as used to control for induction efficiency.
ecithin:cholesterol acyl transferase (LCAT), CETP,
nd phospholipid transfer protein activity. The fractional
holesterol esterification rate (FER) and LCAT activity
ere assayed with standard methodology (11,12). The
ETP and phospholipid transfer protein (PLTP) activity
as determined as described previously (12).
ipid and lipoprotein assays. The 2D-PAGGE was per-
ormed as described previously (13). Plasma lipoproteins
ere separated by high-performance liquid chromatography
n a Superose-6HR column (Amersham Pharmacia Bio-
ech, Piscataway, New Jersey), and cholesterol content was
etermined as described previously (14). Serum apoA-I,
poB, HDL-C, LDL-C, total cholesterol, and triglycerides
ere measured on an Olympus AU640 or AU2700 (Olym-
us, Tokyo, Japan) immunoautoanalyzer at MPI Re-
earch, Inc. ltatistical analysis. IN VITRO AND AGM STUDIES. Results
ere compared by paired 2-tailed t test.
UMAN STUDIES. Results were compared by paired 2-tailed
test when compared with baseline (day 1, pre-treatment)
nd by 1-way analysis of variance when compared with
lacebo.
esults
rigins of RVX-208. Expression of the APOA1 gene is
egulated by many components, including nuclear transcrip-
ion factors. However, it is difficult to manipulate the
ctivity of such factors. Instead, we sought to identify novel
ompounds capable of directly raising apoA-I production.
he lead compound, RVX-208, was found with a HepG2
ell-based assay to screen agents with the potential to raise
poA-I production. The RVX-208 is a small novel synthetic
olecule belonging to the Quinazoline family (Fig. 1A), a
ompound class that has been used across a variety of
herapeutic areas.
The RVX-208 compound has a molecular weight below
00 Da and obeys the Lipinski et al. (15) and Veber et al.
16) guidelines for drug-like characteristics. It is soluble in
cidic (pH 1), aqueous media (3.0 to 3.5 mg/ml) and has
ood metabolic stability in the monkey, on the basis of
ncubation with liver microsomes (90% remaining after 30
in incubation). The pharmacokinetics and oral bioavail-
bility of RVX-208 were studied in a number of species,
ncluding the monkey, indicating that the compound was
enerally well-absorbed orally. In cynomolgus monkeys, it
ossessed low systemic clearance (5 ml/min/kg), moderate
olume of distribution at steady state (Vss) of 0.8 l/kg, a
elatively short half-life (1.5 h), and an oral bioavailability of
4%. A single oral dose of 10 mg/kg produced a plasma
xposure of approximately 14,500 h  ng/ml. Mouse
tudies showed that most RVX-208 was localized in tissues
hat express apoA-I, the small intestine, and liver, at
oncentrations several-fold higher than those in plasma
data not shown). Further characterization of the apoA-I–
levating capacity of RVX-208 was pursued, given its
romising pharmacological and drug-like properties.
VX-208 induces apoA-I mRNA and de novo synthesis
f apoA-I in cultured HepG2. To determine whether
VX-208 affected HDL biogenesis, we measured apoA-I
RNA expression, de novo apoA-I synthesis, and nas-
ent HDL formation in HepG2 cells. Results (Fig. 1B)
howed that RVX-208 significantly increased apoA-I
RNA and protein mass in a dose-dependent manner (0
o 60 mol/l). Additionally, treatment of HepG2 with
VX-208 (60 mol/l) for varying periods of time showed
significant increase in apoA-I released into the medium
r associated with cell lysates for 24- and 48-h time
oints compared with untreated cells (Fig. 1C). As
xpected, RVX-208 had no significant effect on 2-
acroglobulin (2M) levels used as a control for proteinoading. The increase in apoA-I released into media from
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June 8, 2010:2580–9 Effect of RVX-208 Compound on HDL Metabolismells treated with RVX-208 (60 mol/l) for 48 h was
easured by Western-blot (Fig. 1C) or enzyme-linked
mmunoadsorbent assay (Fig. 1B) were similar at 2.5-
old. The 2D-PAGGE analysis of the medium from cells
reated with RVX-208 (60 mol/l, 48 h) revealed in-
reased abundance of both lipid-poor pre-–migrating
nd larger -LpA-I particles (Fig. 1D, right), compared
ith untreated cells (Fig. 1D, left).
The fate of nascent apoA-I was assessed with a pulse-
hase protocol. In cells treated with RVX-208, there was
ncreased incorporation of the radiolabel into apoA-I that
ppeared intracellularly at 20 min (peak incorporation) (Fig. 2A,
eft) and extracellularly at 180 min chase time (peak secre-
ion) (Fig. 2A, right). Densitometric quantification of
35S]-apoA-I from these studies is shown in Fig. 2B.
ellular toxicity after RVX-208 treatment was assessed by
3H]-adenine leakage. No significant increase of [3H]-
denine release was observed under the concentrations of
Figure 1 Effect of RVX-208 on ApoA-I mRNA and Biogenesis of
(A) General structure of RVX-208, belonging to the quinazoline family. (B) HepG2
[DMSO]) for 48 h. Apolipoprotein (Apo)A-I messenger ribonucleic acid (mRNA) and
reaction normalized to cyclophilin and enzyme-linked immunoadsorbent assay norm
RVX-208 for different time points (12, 24, and 48 h). Equivalent volumes of media
gel electrophoresis in duplicate. 2-macroglobulin (2M) controlled for protein load
umes of media were separated by 2-dimensional polyacrylamide nondenaturing gra
levels of lipid-poor pre-–migrating and larger 1-lipoprotein particles containing apVX-208 used in the experiments described in the preced- ang text (data not shown). These findings show that RVX-
08 increases endogenous apoA-I production.
VX-208 increases serum apoA-I and HDL-C in AGMs.
ext, RVX-208 was tested in male AGMs, because this
odel shows many similarities to human subjects in the
ffects of dietary cholesterol and fatty acids on plasma
ipoproteins and cholesterol metabolism. Furthermore,
GMs shared sufficient preclinical pharmacokinetic char-
cteristics with cynomolgus species, which were used for
harmacological testing as described in the preceding text
17). The AGMs received RVX-208 (60 mg/kg) or vehicle
nce daily for 63 days. The RVX-208 treatment produced a
arked and significant increase in both apoA-I and
DL-C levels of 133  4 mg/dl versus 203  5 mg/dl
53%) and 57  2 mg/dl versus 111  2 mg/dl (97%),
espectively, by 28 days when baseline was compared with
VX-208 treatment (Table 1). These increases were sus-
ained throughout the duration of treatment, yielding aver-
ent HDL in HepG2
ere treated with RVX-208 (0 to 60 mol/l) or control (dimethylsulphoxide
levels were analyzed by quantitative reverse-transcription polymerase chain
to albumin, respectively. (C) HepG2 were treated with or without 60 mol/l
crograms of cell lysate were separated by sodium dodecyl sulfate polyacrylamide
) HepG2 cells were treated or not treated with RVX-208 for 48 h, and equal vol-
gel electrophoresis. Media from RVX-208–treated cells had significantly higherNasc
cells w
protein
alized
or mi
ing. (D
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oA-I.ge apoA-I and HDL-C values on day 63 of treatment of
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g/dl versus 112  4 mg/dl (97%), respectively (baseline
s. RVX-208–treated). Similarly, apoA-I and HDL-C
evels increased significantly and in a dose-dependent man-
er in the escalating dose study (Online Table 1). The
VX-208 treatment did not affect serum LDL-C or apoB
oncentrations. Although RVX-208 treatment given at 60
g/kg once daily increased total serum triglyceride levels
Table 1), the same dose given at 30 mg/kg twice daily had
o effect on triglyceride levels (Online Table 1). These
ndings show that RVX-208 given orally to AGMs in-
reases serum levels of both apoA-I and HDL-C.
ffect of RVX-208 on serum levels of HDL species. To
urther explore the effects of the compound, we examined
hether RVX-208 affected HDL populations. There were 2
Intracellular (cell pellet)
B
A
Figure 2 Effect of RVX-208 on De Novo Synthesis of ApoA-I in
(A) De novo synthesis of apolipoprotein (apo)A-I was assessed with [35S]methionine/
RVX-208 for 48 h before exposure to the radiolabeled amino acid. Autoradiography wa
fraction, left) and media (extracellular fraction, right) separated with sodium dodecyl s
apoA-I in intracellular and extracellular fractions are shown. Experiments were perform
erum Levels of ApoA-I, HDL-C, ApoB And Lipids of Vehicle and RVTable 1 Serum Levels of ApoA-I, HDL-C, ApoB And Lipids of Veh
ApoA-I HDL-C Total C
Vehicle (n  6)
Baseline 134 10 58 5 108
Day 28 153 14 70 6 123
Day 42 145 10 68 6 115
Day 63 154 12 71 5 121
Day 64 (washout) 142 12 63 6 116
Day 77 (washout) 149 12 66 6 115
RVX-208 (n  6), 60 mg/kg/day
Baseline 133 4 57 2 104
Day 28 203 5* 111 2* 160
Day 42 209 5* 106 3* 160
Day 63 213 9* 112 4* 170
Day 64 (washout) 191 8* 105 3* 135
Day 77 (washout) 170 6 77 3 125alues are mg/dl. *p  0.05 compared with vehicle samples taken at the same treatment day.arts to this study. The first was the use of 2D-PAGGE
nd high-performance liquid chromatography analysis of
lasma to assess qualitative changes; the second required use
f ND-PAGGE and densitometric scanning for quantitative
nalysis. The 2D-PAGGE analysis of apoA-I-containing
articles revealed that both pre-1-LpA-I and larger 1-
pA-I subpopulations were significantly increased in RVX-
08 treated serum (Fig. 3, top). Lipoprotein separation by
igh-performance liquid chromatography showed, consistent
ith this finding, increased total cholesterol in the HDL
raction and a left-shifted HDL-C peak, indicating a larger
DL-particle size after treatment (Fig. 3, bottom).
To further examine the HDL size distribution, serum
as separated by ND-PAGGE, and apoA-I–containing
articles were detected with an iodinated anti-apoA-I an-
Extracellular (media)
2
e as described in the Methods section. HepG2 cells were treated with 60 mol/l
to detect radiolabeled apoA-I immunoprecipitated from labeled cells (intracellular
polyacrylamide gel electrophoresis. (B) Representative densitometry of radiolabeled
e in duplicate, and results were pooled. The values are mean  SD. *p  0.001.
ated Monkeysand RVX-Treated Monkeys
erol LDL-C Triglycerides Total Phospholipids ApoB
36 3 22 4 155 13 28 2
41 5 32 6 174 19 32 4
36 3 39 6 145 10 30 3
46 2 31 2 176 17 34 1
33 2 19 1 152 13 28 2
41 4 26 3 152 10 33 3
36 2 28 3 157 13 31 2
41 3 57 8* 256 10* 36 2
43 3 69 5* 211 10* 37 2
46 3 64 10* 285 8* 37 1
37 3 39 3 273 9* 32 1
44 3 30 3 178 8 36 1HepG
cystein
s used
ulfate
ed twicX-Treicle
holest
 7
 10
 8
 9
 12
 7
 3
 4*
 5*
 9*
 17
 11
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June 8, 2010:2580–9 Effect of RVX-208 Compound on HDL Metabolismibody (Fig. 4, top). The HDL subpopulations were quan-
ified by densitometry. The RVX-208 (60 mg/kg; once
aily) significantly increased both pre-1-LpA-I and larger
1-LpA-I as compared with vehicle, whereas levels of
2-LpA-I were significantly decreased (Fig. 4, bottom). No
ignificant change in 3-LpA-I particles was observed. As
xpected, the HDL size distribution of RVX-208–treated
onkeys normalized after the washout period (Fig. 4, top)
day 77). Importantly, there was no difference between the
uman apoA-I antibody (Biodesign) and the monkey
poA-I antibody (from Dr. John S. Parks) in detecting
onkey HDL species (data not shown). Together these
ata show that the RVX-208–stimulated increase in HDL
s accompanied by changes in the profile of this class of
articles.
VX-208 stimulates cellular cholesterol efflux via different
athways. The RVX-208–induced rise in apoA-I and pre-
-HDL should enhance cholesterol efflux. Therefore, we
easured ABCA1, ABCG1, and SR-BI–mediated choles-
erol efflux with serum from RVX-208 and vehicle-treated
GMs. Cyclic adenosine monophosphate-stimulated J774
acrophages, BHK-cells stably over-expressing ABCG1, and
u5AH were used as cellular models of ABCA1, ABCG1,
nd SR-BI–mediated cholesterol efflux, respectively. Data
Fig. 5) showed a significant increase in cholesterol efflux
ediated by any 1 of the pathways (Figs. 5A to 5C) across
ll treatment days with levels returning to baseline upon
Figure 3 2D-PAGGE and HPLC Analysis of RVX-208–Modified H
Serum (25 l) from monkeys treated for 63 days with vehicle or RVX-208 (60 mg/
2-dimensional polyacrylamide nondenaturing gradient gel electrophoresis (2D-PAGG
body (top panels). Both pre-1-lipoprotein particles containing apoA-I (LpA-I) and la
Serum (250 l) from vehicle- or RVX-208–treated monkeys was separated by high
described in the Methods section (bottom panels). A representative 2D-PAGGE an
high-density lipoprotein.ashout. Because RVX-208–enhanced cholesterol efflux nctivity had reached near plateau levels by 28 days of
reatment, we pooled data from all RVX-208 treatment
eriods (28, 42, and 63 days) versus control subjects
Fig. 5D) for each transporter (ABCA1: 7.6 1.2% vs. 15.4
1.7%; ABCG1: 19.9  3.3% vs. 30.3  4.5%; and
R-BI: 8.7  1.3% vs. 14.7  1.0%; vehicle vs. RVX-208–
reated; p  0.001 for ABCA1 and SR-BI, p  0.01 for
BCG1, n  4/group).
VX-208 decreases serum LCAT activity but has no
ffect on CETP or PLTP activities. The RVX-208 was
hown to increase apoA-I and HDL-C levels and to cause
rofound changes in the HDL-size distribution. Because
hese alterations might be due to changes in the activities of
DL-remodeling enzymes induced by RVX-208, we ex-
mined the activities of LCAT, CETP, and PLTP. Both
he FER and exogenous LCAT activity were significantly
ecreased in the serum of RVX-208–treated monkeys as
ompared with control subjects (FER: 33.3 9.9 vs. 59.0
.5, p  0.01, day 63; exogenous LCAT: 49.0  15.8 vs.
3.8  11.3, p  0.05, day 63). Previous studies have
ocumented that subjects treated with CETP inhibitors
ossess larger HDL particles (18). Therefore, the increase in
arger 1-LpA-I in RVX-208–treated monkeys might arise
rom CETP inhibition. However, no significant difference
n CETP activity was observed between RVX-208– and
ehicle-treated monkeys (data not shown). Similarly, no
ignificant difference in PLTP activity was observed (data
e daily) were separated along with radiolabeled molecular weight markers by
olipoprotein (Apo)A-I–containing particles were detected by iodinated apoA-I anti-
1-LpA-I subpopulations were significantly increased in RVX-208–treated serum.
mance liquid chromatography (HPLC), and the total cholesterol was measured as
C (n  4) from 1 RVX-208–treated and 1 control monkey are shown. HDL DL
kg onc
E). Ap
rger 
-perfor
d HPLot shown).
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Effect of RVX-208 Compound on HDL Metabolism June 8, 2010:2580–9VX-208 increased apoA-I, pre-HDL, and cholesterol
fflux in man. The favorable features of RVX-208 action in
he AGMs prompted us to test the compound in humans.
era from the 18 subjects receiving multiple and varying
oses (2 to 8 mg/kg/day) of RVX-208 for 7 days were
ssayed for 4 parameters: apoA-I, HDL-C, pre-1-LpA-I
nd ABCA1 cholesterol mediated efflux as described. The
esults showed that all doses of RVX-208 tested induced a
ise in the levels of the 4 parameters. The use of analysis of
ariance to compare these rises above the baseline versus
lacebo was significant in some groups but not all. Given
he limited number of treated subjects, the value of these
arameters was pooled regardless of dose administered.
esults (Fig. 6) showed that plasma apoA-I was 10% higher
p  0.05) in RVX-208–treated subjects compared with
lacebo-treated subjects. Similarly, there was a marked
ncrease in pre-1-HDL levels and ABCA1-mediated cho-
esterol efflux (Fig. 6) of 42% and 11%, respectively (p 
.05). Both HDL-C and larger -HDL particles showed
rends toward higher levels in the treated patients of 10%
nd 21%, respectively, but these increases were not statisti-
ally significant. The ApoB, LDL-C, and triglyceride levels
ere within the reference range (data not shown). Together
he preceding findings show that RVX-208 increases
Figure 4 Effect of RVX-208 on HDL Subfraction Distribution
Serum (25 l) from RVX-208–treated (n  3) or control monkeys (n  4) were sep
Methods section. ApoA-I–containing particles were detected by iodinated apoA-I an
each HDL subfraction as percentage of the total. The RVX-208 significantly increas
levels of 2-LpA-I were significantly decreased. Plotted values are mean  SD of t
son with protein standards. *p  0.05. Abbreviations as in Figure 3.poA-I, pre-1-HDL, and cholesterol efflux in humans. riscussion
n this report, we show that a novel small molecule,
VX-208, increases plasma apoA-I and HDL-C and mod-
lates the biochemical properties, metabolism, and function
f HDL. The RVX-208 tested in vitro on HepG2 cells
ncreased apoA-I mRNA and protein levels in a dose-
esponsive manner (Fig. 1B). This finding is significant,
ecause the liver is proposed to be the major source of
lasma HDL-C (19) and hepatic ABCA1 is a significant
ontributor to plasma HDL-C concentrations (20).
To confirm that RVX-208 increased de novo apoA-I-
rotein synthesis, we used [35S]methionine/cysteine pulse-
hase studies (Fig. 2). The RVX-208 stimulated intracellu-
ar synthesis of apoA-I (Figs. 2A and 2B) that was secreted
nto the medium. The increased production of apoA-I was
ssociated with a rise in the abundance of the larger
ascent–LpA-I and lipid-poor pre-–migrating particles
Fig. 1D). These in vitro studies show that RVX-208
ncreases apoA-I synthesis in and HDL secretion from
epG2 cells.
Next, we proceeded to in vivo studies using AGMs where
VX-208 (60 mg/kg once daily or 30 mg/kg twice a day)
reatment had no effect on non–HDL-C levels but led to
by nondenaturing gradient gel electrophoresis (5% to 35%) as described in the
(top panel) and quantitated by densitometry, by expressing detected apoA-I in
th pre-1-LpA-I and larger 1-LpA-I versus vehicle at each time point, whereas
e separation (bottom panels). The molecular sizes were determined by compari-arated
tibody
ed bo
riplicatobust increases in serum apoA-I and HDL-C levels of 60%
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June 8, 2010:2580–9 Effect of RVX-208 Compound on HDL Metabolismnd 97%, respectively, by day 63 of treatment (Table 1,
nline Table 1). A 24-h washout failed to reduce pharma-
odynamic effects of RVX-208, as reflected by the sustained
ncrease in HDL-C (Table 1). This finding fits with the
rolonged plasma residence time of mature HDL (4 to 5
ays) in humans and monkeys (21,22). The RVX-208–
nduced elevation of serum apoA-I and HDL-C was
ccompanied by changes in the HDL size distribution
Figs. 3 and 4). This observation in vivo mirrored the
ndings in HepG2 cells (Fig. 1D).
Sera from RVX-208–treated AGMs had more pre-1-
pA-I and the larger 1-LpA-I particles but less 2-LpA-I
Fig. 4). This shift in the HDL distribution pattern might
e due to the direct effect of RVX-208 on the biogenesis of
ascent apoA-I-containing particles in the liver and intes-
ine. Alternatively, these changes might arise from an
ndirect effect of RVX-208 on plasma factors—including
CAT, CETP, and PLTP—that are known to affect HDL
Figure 5 Serum From Monkeys Treated With RVX-208 Stimulat
Serum from RVX-208–treated (n  4) or control (n  4) monkeys were analyzed fo
lated J774 (A), baby hamster kidney over-expressing ABCG1 (B), and Fu5HA (C) w
tion. Cells were exposed to serum (2%) from vehicle- and RVX-208–treated monke
from triplicate analysis. The line illustrates the average efflux/group. The combine
controls are presented in D. *p  0.05; **p  0.01. SR-BI  scavenger receptoroncentration, composition, and subpopulation distribution i23). Data in the current study support both possibilities.
pecifically, exogenous LCAT activity and FER were sig-
ificantly decreased in serum of RVX-208–treated mon-
eys. However, the cause of this reduction is unclear.
ecreased FER might arise from inability of LCAT to use
arger 1-LpA-I particles generated by RVX-208 as a
ubstrate or to the reduction of 2-LpA-I species after
reatment (Fig. 3). This idea is consistent with a previous
tudy showing the inverse relationship between FER and
igh plasma levels of the large HDL2b particles (24).
hether decreased LCAT activity impacts on atheroscle-
osis is controversial (25). In studies of a large family with
CAT deficiency, there was no observed increase in ACVD
ver 25 years (26).
The RVX-208–induced shift to larger HDL particles
ould have important therapeutic implications for ACVD.
ndeed, previous studies showed ACVD patients to have
ower levels of the larger 1-HDL than control subjects,
holesterol Efflux
ability to mediate cholesterol efflux. Cyclic adenosine monophosphate-stimu-
diolabeled for 24 h with [3H]free cholesterol as described in the Methods sec-
4 h at 37°C. Each data point represents the mean efflux for an individual animal
from all treatment periods (28, 42, and 63 days) versus day 77 wash-out or
B type I.es C
r their
ere ra
ys for
d data
classndependently of HDL-C, suggesting that these larger
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Effect of RVX-208 Compound on HDL Metabolism June 8, 2010:2580–9articles might have an atheroprotective role (27,28).
dditionally, progression of coronary atherosclerosis in
ounger patients who survive myocardial infarcts was in-
ersely associated with the largest HDL particles (29).
lthough CETP-deficient individuals or treatment with
ETP-inhibitors leads to more and larger HDL particles
18), whether they reduce ACVD remains controversial
30), because CETP might participate in RCT. The in-
rease in larger 1-LpA-I species in RVX-208–treated
onkeys was not attributed to CETP inhibition but likely
ue to de novo synthesis.
The protective role of HDL against ACVD is believed to
rise from the flux of cholesterol via RCT pathway (2,3,5).
he RVX-208–induced rise in serum apoA-I and HDL-C
orrelated with enhanced cholesterol efflux activity mediated
y ABCA1, ABCG1, and SR-BI-dependent pathways
Fig. 4). The ability of RVX-208 to enhance efflux likely
rises from the increased total mass of HDL comprising
ore pre-1-LpA-I (Figs. 1D and 3). This change in HDL
rofile is expected to promote RCT, especially from mac-
ophages, which are particularly reliant on the ABCA1
athway (31). Indeed, pre-1-LpA-I has been shown to be
he initial acceptor of cell-derived cholesterol and lipid-free
poA-I and pre-1-LpA-I, the preferred substrates for
BCA1 (32).
The RVX-208 treatment also enhanced ABCG1 and
R-BI–mediated cholesterol efflux (Fig. 5). Recently,
BCG1 was shown to mediate macrophage cholesterol
Figure 6 Effects of RVX-208 in Humans
To determine whether RVX-208 had pharmacodynamic effects, serum samples
from the 18 subjects receiving multiple and varying doses of RVX-208 were
examined. Depicted are the increases in serum apolipoprotein (apo)A-I, high-
density lipoprotein cholesterol (HDL-C), pre-1-lipoprotein particles containing
apoA-I, and ABCA1-mediated cholesterol efflux from pooled data regardless of
dose. *Significant elevation (p  0.05) in a parameter from RVX-208–treated
subjects compared with placebo. Although HDL-C levels trended higher, p 
0.09.fflux to mature and nascent LpA-I in vitro. Furthermore,
nice lacking ABCG1 display lipid accumulation in macro-
hages (33). The SR-BI facilitates bidirectional flux of
holesterol between cells and HDL (34), and it is likely that
his receptor promotes selective uptake of free cholesterol
nd cholesteryl ester from larger HDL particles generated
y RVX-208 in the liver. Our finding that cholesterol efflux
ediated by all 3 pathways is enhanced by RVX-208
uggests it impacts the physicochemical properties and
holesterol efflux function of HDL.
The promising features of RVX-208 action in vitro and
n AGMs prompted progression to a study in humans.
ssessment of RVX-208–induced effects (Fig. 6) after 7
ays of treatment showed promising results. Despite the
imited number of subjects, short duration of treatment,
nd lack of knowledge regarding optimal dosing, the
reated subjects had statistically significant increases in
poA-I protein, pre-˜HDL, ex vivo ABCA1-mediated
holesterol efflux, and a trend toward increases in
DL-C and large -HDL. This early dataset in humans
upports the notion that RVX-208 treatment increases
poA-I synthesis and HDL functionality with the poten-
ial to reduce atherosclerosis.
Improving the functional capacity of HDL to remove
holesterol from macrophage foam cells in order to stabilize
nd possibly regress atherosclerotic plaques is a highly
esirable goal in treating ACVD. A small molecule with the
apacity to increase apoA-I production and plasma levels of
poA-I and HDL-C is conceptually an ideal way to achieve
unctional HDL. In vivo treatment with RVX-208 resulted
n a significant increase in serum apoA-I and HDL-C
evels. As expected, these changes led to improved HDL-
ediated cholesterol efflux function. However, we wish to
ake clear that no attempt was made to claim that RVX-
08 has atheroprotective effects. Ongoing studies that ex-
mine the effects of RVX-208 on the HDL metabolic
athway in humans and animals will define the therapeutic
otential of this compound in treating atherosclerotic car-
iovascular disease.
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